Analysts’ recommendations and target price
Wall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing price on March 27. Analysts reduced the company’s target price from $179.39 in January to $175.89 in February and reiterated this target price in March.
The current consensus analyst recommendation for the stock is a “buy.”
Of the 24 analysts covering bluebird bio, eight are recommending “strong buys,” eight are recommending “buys,” and eight are recommending “holds.” The highest and lowest target price estimates for the company are $292 and $120, respectively.
On March 27, bluebird bio closed at $147.55, 3.44% lower than its previous closing price, 68.65% higher than its 52-week low of $87.49, and 35.34% lower than its 52-week high of $199.70.
Based on its closing price on March 27, bluebird bio has reported returns of -3.93% in the last week, -3.32% in the last month, and 61.70% in the last quarter. The company has reported returns of 5.81% in the last half year, -21.91% in the last year, and 48.74% year-to-date.
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it had entered into a definitive agreement to acquire gene therapy player Spark Therapeutics (ONCE) for a total consideration of $4.3 billion. This news gave a boost to the share prices of many gene therapy players, including bluebird bio, which closed at $149.91, 14.16% higher than its previous closing price.
In 2018, bluebird bio reported revenue of $54.58 million, a YoY (year-over-year) rise of 54.06%. Analysts expect the company to grow its revenue by 10.56% YoY to $60.34 million in 2019, 218.75% to $192.34 million in 2020, and 158.92% to $498 million in 2021.
In 2018, bluebird bio reported non-GAAP (generally accepted accounting principles) EPS of -$10.68, a YoY fall of 38.52%. Analysts expect the company to see YoY changes in its non-GAAP EPS of -9.78% to -$11.72 in 2019, 10.21% to -$10.53 in 2020, and 31.39% to -$7.22 in 2021.